Warning: The NCBI web site requires JavaScript to function. more...
Incretins in the ICU: is insulin on its way out?
Kovalaske MA, Gandhi GY.
Crit Care. 2009;13(4):161. Epub 2009 Jul 2.
Related citations
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Van Gaal LF, Gutkin SW, Nauck MA.
Eur J Endocrinol. 2008 Jun;158(6):773-84. Epub 2008 Mar 5. Review.
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M.
Crit Care. 2009;13(3):R67. Epub 2009 May 13.
Incretin-based therapy of type 2 diabetes mellitus.
Knop FK, Vilsbøll T, Holst JJ.
Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.
Incretin based therapies for type 2 diabetes mellitus.
Ghosh S, Collier A, Elhadd T, Malik I.
J Indian Med Assoc. 2008 Jun;106(6):373-4, 383, 388.
Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial.
Sourij H, Schmölzer I, Kettler-Schmut E, Eder M, Pressl H, Decampo A, Wascher TC.
Diabetes Care. 2009 Sep;32(9):1669-71. Epub 2009 Jun 15.
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ, Cassidy RS, Green BD.
Br J Pharmacol. 2009 Aug;157(8):1340-51. Review.
Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ.
Pharmacol Ther. 2009 Oct;124(1):113-38. Epub 2009 Jun 21. Review.
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
Gallwitz B.
Treat Endocrinol. 2005;4(6):361-70. Review.
The entero-insular axis: implications for human metabolism.
Ranganath LR.
Clin Chem Lab Med. 2008;46(1):43-56. Review.
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Girard J.
Diabetes Metab. 2008 Dec;34(6 Pt 1):550-9. Epub 2008 Nov 25. Review.
[Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B, Lenart-Lipińska M, Nowakowski A.
Endokrynol Pol. 2007 Nov-Dec;58(6):522-8. Review. Polish.
Glucagon-like peptide 1 based therapy for type 2 diabetes.
Yu BS, Wang AR.
World J Pediatr. 2008 Feb;4(1):8-13. Review.
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF.
Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31. Review.
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E, Sesti G.
Clin Ther. 2009 Nov;31(11):2472-88. Review.
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI.
Mymensingh Med J. 2009 Jan;18(1):113-24. Review.
Incretins: the novel therapy of type 2 diabetes.
Thongtang N, Sriwijitkamol A.
J Med Assoc Thai. 2008 Jun;91(6):943-54.
The incretin system and its role in type 2 diabetes mellitus.
Holst JJ, Vilsbøll T, Deacon CF.
Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. Epub 2008 Aug 20. Review.
Combination pharmacotherapy with incretins: what works best and when?
Over RK, Ratner RE.
Curr Diab Rep. 2008 Oct;8(5):361-7.
Incretin-based therapies in type 2 diabetes mellitus.
Chia CW, Egan JM.
J Clin Endocrinol Metab. 2008 Oct;93(10):3703-16. Epub 2008 Jul 15. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on